TL;DR
Gaithersburg and the Maryland I-270 corridor host the MedImmune (AstraZeneca biologics), Novavax, and Emergent BioSolutions footprints plus a wave of NIH-adjacent biotech operators tied to federal contracting. Insurance programs here have a distinctive shape: standard clinical-stage biotech D&O architecture plus biologic-specific products liability towers plus federal-contracting overlay (BARDA, NIAID, NIH grant terms), which produces specific insurance schedule demands that traditional commercial-only biotech programs do not address.
Maryland I-270
Gaithersburg biotech insurance - Maryland I-270 corridor, NIH-adjacent operators.
The I-270 corridor running north from Bethesda through Rockville to Gaithersburg and Frederick is the densest biotech cluster on the East Coast outside of Cambridge/Boston. The cluster is anchored by three large operators - MedImmune (AstraZeneca's biologics arm), Novavax, and Emergent BioSolutions - plus a long bench of clinical-stage operators tied to NIH, NIAID, and BARDA federal contracting. The insurance underwriting picture is shaped by that federal-contracting overlay in ways that distinguish it from coastal biotech clusters.
Cluster characteristics
Federal contracting reshapes the insurance schedule.
MedImmune (Gaithersburg AstraZeneca biologics) anchors the corridor as one of the largest biologic manufacturing footprints on the East Coast. Insurance programs for MedImmune-adjacent contract manufacturers and CROs run sponsor MSA insurance demands typical of large pharma biologic supplier arrangements.
Novavax (Gaithersburg) and the broader vaccine development cluster carry insurance program characteristics distinct from small-molecule biotech: biologic-specific products liability towers, federal contract performance bonds, and Public Readiness and Emergency Preparedness Act (PREP Act) interaction questions for pandemic-period indemnification structures.
Emergent BioSolutions (Gaithersburg HQ + Baltimore manufacturing) operates across contract manufacturing for federal biothreat preparedness products and commercial biologics. The contract manufacturing footprint at Baltimore Bayview produces distinctive sponsor MSA insurance schedule requirements layered on top of federal contract terms.
NIH-adjacent clinical-stage biotech operators tied to BARDA, NIAID, and NIH grant funding face federal contracting insurance requirements that traditional commercial-only biotech programs do not address: specific bonding requirements, Defense Base Act for any non-US trial sites, and contract performance representations tied to the federal contract terms.
Maryland regulatory overlay
MOPDPA, MD Board of Pharmacy, and federal-state intersection.
Maryland enacted the Maryland Online Data Privacy Act (MOPDPA) which took effect October 2025, layering consumer-protection and data-privacy obligations on top of HIPAA for clinical health data flows. Cyber liability programs for Gaithersburg biotech should explicitly cover MOPDPA defense and notification expense.
For 503A and 503B compounding pharmacies in the Maryland portion of the I-270 corridor, the Maryland Board of Pharmacy operates an active sterile compounding inspection program that interacts with FDA inspection of 503Bs. Operators in this segment should expect parallel state and federal inspection scrutiny.
Securities-class-action posture in District of Maryland is moderate. D&O architecture for Maryland-headquartered post-IPO biotech should anticipate standard clinical-stage disclosure risk; federal contract performance disclosure is a distinct exposure that traditional D&O may not address without specific endorsement.
I-270 biotech coverage review